A Phase 1 interventional study of 90Y-NM600 in Metastatic Cancer, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.
Sponsored by University of Wisconsin, Madison · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Neoplasm Metastasis by University of Wisconsin, Madison — 4 open to participants now, 5 under way, none of them phase 3. Neoplasm Metastasis · University of Wisconsin, Madison.
Among the 14 studies in Neoplasm Metastasis by University of Wisconsin, Madison, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 13th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →4 of the 14 studies in Neoplasm Metastasis by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 8–18
By country, each count listing its studies:
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 18 across the 12 interventional studies, 228 across the 1 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.
Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.
2 of the studies in Neoplasm Metastasis by University of Wisconsin, Madison that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06067503University of Wisconsin, MadisonBiomarkers to Detect Endocrine Therapy Resistance | 2026-12 |
| NCT04020276University of Wisconsin, MadisonOAR-Based, Dose Escalated SBRT With Real Time Adaptive MRI Guidance for Liver Metastases | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Neoplasm Metastasis by University of Wisconsin, Madison, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.
This is a safety study of 86Y-NM600 and 90Y-NM600 and a dose finding study for 90Y-NM600 in patients with metastatic cancers who are receiving an anti-PD-1 or anti-PD-L1 therapy, have persistent disease that is stable or potentially progressive, and will be continuing anti-PD-1 or anti-PD-L1 therapy for another imaging interval per the treating physician. The imaging agent 86Y-NM600 will be injected, and serial positron-emission tomography (PET)/computed tomography (CT) imaging will be performed to enable dosimetry calculations that will be used to determine eligibility for 90Y-NM600.
Phase 1a of the study (dose finding) will enroll 6-24 participants into a 3x3 dose finding plan where 3 participants start at Level 1 (below) and the number of participants with dose limiting toxicities (DLTs) will inform the next 3 participants:
Dosing Plan:
Phase 1b (expansion cohort) may enroll up to an additional 36 participants (18 into a single dose cohort, 18 into a multi-dose cohort) with metastatic cancer.
The primary endpoints are to determine the safety of administering 86Y-NM600 for imaging and 90Y-NM600 for delivering radiation in patients with metastatic cancer who are receiving standard-of-care anti-PD-1 or anti-PD-L1 therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject has adequate hepatic function as defined by:
The participant has adequate hematologic function without Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) injection or transfusion in the prior 7 days, as evidenced by:
Exclusion Criteria:
Chemotherapy, radiotherapy, or major surgery within 3 weeks prior to study enrollment (this will be greater than 5 weeks prior to 90Y-NM600 therapy).
a. For patients receiving prior radiation therapy, the dose to tumor, kidneys, liver, and bone marrow must be recorded, if available.
Concurrent treatment with any other systemic anti-cancer or agents other than an , anti-PD-L1, anti-CTLA-4, or anti-LAG-3 antibody. Subjects cannot be receiving concomitant chemotherapy, experimental therapy or any other therapy not otherwise outlined by the trial for the purposes of anti-cancer treatment.
b. Palliative external beam radiation therapy may be delivered to patients during this study if deemed necessary and safe by the treating physician.
c. Participants can be receiving dual immune checkpoint inhibition with an anti-CTLA-4 antibody or an anti-LAG-3 antibody in addition to an anti-PD-1 or anti-PD-L1 therapy.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 mCi x 1 90Y-NM600
Drug: 90Y-NM600
35 mCi x 1 90Y-NM600
Drug: 90Y-NM600
70 mCi x 1 90Y-NM600
Drug: 90Y-NM600
105 mCi x 1 90Y-NM600
Drug: 90Y-NM600
140 mCi x 1 90Y-NM600
Drug: 90Y-NM600
Informed by Phase 1A
Drug: 90Y-NM600
Informed by Phase 1A and Single Dose Phase 1B
Drug: 90Y-NM600
NM600 is a tumor-selective, pan-cancer, targeted radionuclide therapy (TRT) with theranostic capacity
Also known as: alkylphosphocholine (APCh) analog
Toxicities greater than or equal to Grade 3 at least possibly related to 86Y-NM600
Toxicities greater than or equal to Grade 3 at least possibly related to 86Y-NM600 by day 7 (greater than 10 half-lives of 86Y) after 86Y-NM600 injection, as defined by the NCI CTCAE version 5.0.
Time frame: baseline screening, Day 7 after 86Y-NM600 injection
Toxicities greater than or equal to Grade 3 at least possibly related to 90Y-NM600
Toxicities greater than or equal to Grade 3 at least possibly related to 90Y-NM600 by day 42 after final 90Y-NM600 injection, as defined by the NCI CTCAE version 5.0. Time points of investigation include: * baseline screening * Phase 1A: post injection week 1, week 2, week 3, week 4 * Phase 1B: 7 days after each injection, 30 days and 42 days after final injection
Time frame: up to 9 months on study
Pharmacokinetics of Y-NM600: Blood concentration verse time curve
Blood concentration verse time curve, blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, \*2.0 hours, 4.0 hours, 24 hour, and \*48 hours after infusion (\*Phase 1A only)
Time frame: 3-5 min after end of infusion, 0.5 hours, *2.0 hours, 4.0 hours, 24 hour, and *48 hours after infusion (*Phase 1A only)
Pharmacokinetics of Y-NM600: Time to reach maximum concentration of Y-NM600 in Blood
Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, \*2.0 hours, 4.0 hours, 24 hour, and \*48 hours after infusion (\*Phase 1A only)
Time frame: Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, *2.0 hours, 4.0 hours, 24 hour, and *48 hours after infusion (*Phase 1A only)
Pharmacokinetics of Y-NM600: Blood Radioactivity from Y-NM600
Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, \*2.0 hours, 4.0 hours, 24 hour, and \*48 hours after infusion (\*Phase 1A only)
Time frame: Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, *2.0 hours, 4.0 hours, 24 hours, and *48 hours after infusion (*Phase 1A only)
Pharmacokinetics of Y-NM600: Physiological Half-life of Y-NM600
Phase 1a: Blood draws at estimated Cmax 3-5 min after end of infusion (+/- 5 min), 0.5 hours (+/- 15 min), 2.0 hours (+/- 30 min), 4.0 hours (+/- 30 min), 24 hours (+/- 120 min), and 48 hours (+/- 120 min) after infusion. Phase 1b: Blood draws at estimated Cmax 3-5 min after end of infusion (+/- 5 min), 0.5 hours (+/- 15 min), 4.0 hours (+/- 30 min), and 24 hours (+/- 120 min) after infusion. Cumulative urine collection will be done for 6 hours with specific samples collected and pooled at 0.5 hours (+/- 15 min), 3 hours (+/- 30 min), and at 5 hours (+/- 30 min) after infusion.
Time frame: Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, *2.0 hours, 4.0 hours, 24 hours, and *48 hours after infusion (*Phase 1A only)
Proportion of Participants with 2-fold or greater uptake of 86Y-NM600 in tumor site compared to red bone marrow
Assessed via PET/CT 48-72 hours after 86Y-NM600 infusion as Maximum Standardized Uptake Value (SUVmax) at tumor sites previously identified by standard of care imaging and at a site of red bone marrow.
Time frame: 48-72 hours after 86Y-NM600 infusion
Overall Response Rate (ORR) by iRECIST at 12 weeks after final 90Y-NM600 injection (D1)
ORR will include iCR and iPR and will be determined as per iRECIST, by investigator assessment.
Time frame: baseline, standard-of-care imaging 12 weeks after D1
Safe and Effective Dose Level for Phase 1B
A recommended phase 1b single treatment dose level is based on the following criteria: 1) a dose level resulting in less than 33 percent of participants with Dose Limiting Toxicities by 42 days after final 90Y-NM600 injection, 2) the dose level with the greatest ORR among dose levels that meet criteria 1 and the lower dose level if ORR is equal at two dose levels, and 3) the highest dose level that meets criteria 1 if no participants exhibit ORR in any regimen that meets criterion 1. For the multi-dose expansion cohort, the recommended dose will be the single treatment expansion dose level or the next highest dose level for which OLINDA calculations from PET/CT imaging at 48-72 hours after 86Y-NM600 for all enrolled patients predict cumulative mean doses of less than 23 Gy to the kidney, less than 2 Gy to the red bone marrow, and less than 30 Gy to liver in greater 66 percent of participants following three cycles of 90Y-NM600 at the multi-dose expansion cohort dose level.
Time frame: Phase 1A: baseline, Once per week for four weeks after 90Y-NM600 injection and at day 42 after 90Y-NM600 injection, Standard-of-care imaging 8 weeks after D1 of 90Y-NM600
Progression Free Survival (PFS)
PFS is defined as the time from Day 1 of treatment until the criteria for disease progression is met as defined by iRECIST or death as a result of any cause.
Time frame: Day 1 of treatment, Standard-of-care imaging follow-up ~3 and 6 months after Day 1, Time of disease progression (monitored up to 5 years)
Overall Survival (OS)
OS is defined as time from Day 1 of treatment until death as a result of any cause.
Time frame: Day 1 of treatment, Standard-of-care imaging follow-up ~3 and 6 months after Day 1, Time of disease progression, Death (monitored up to 5 years)
Duration of Response
Duration of response is the period measured from the time that measurement criteria are met for immune complete response (iCR), immune partial response (iPR), or immune-related stable disease (iSD) (whichever status is recorded first) until the date that recurrent or iPD is objectively documented.
Time frame: Day 1 of treatment, Standard-of-care imaging follow-up ~3 and 6 months after Day 1, Time of disease progression (monitored up to 5 years)
EORTC QLQ-C30
Determine the impact of 90Y-NM600 on patient-reported health-related quality of life (HRQoL) by assessing the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). The EORTC QLQ-C30 is scored from 0-100 where higher scores indicate a better quality of life.
Time frame: baseline, 1 week after Day 1, 12 weeks after Day 1
EQ-5D Score
Determine the impact of 90Y-NM600 on patient-reported health-related quality of life (HRQoL) by assessing the EQ-5D. The EQ-5D is scored between 0-1 where better quality of life is closer to 1.
Time frame: baseline, 1 week after Day 1, 12 weeks after Day 1
Tumor Heterogeneity
Mean, minimum, and maximum dose predicted for 86Y-NM600 and 90Y-NM600 in tumors greater than 2 cm and for select normal organs \[kidney, liver, red bone marrow, blood (2 cm region of abdominal aorta that is great than 1 cm away from any identified tumor site)\] will be determined from three serial 86Y-NM600 PET/CT images. When feasible, this will be performed for all tumor sites greater than 2 cm in any diameter. If the reading radiologist determines this is not feasible, then 5 tumors greater than 2cm will be randomly chosen and dosimetry evaluated at these sites.
Time frame: PET/CT imaging at 1-6 hours, 18-36 hours, and 48-72 hours after 86Y-NM600 infusion
Tumor Expression of Immune Susceptibility Markers
Expression of PD-L1, MHC-1, VCAM-1, and IFNβ mRNA by polymerase chain reaction (PCR) on CD45- cells isolated from disaggregated tumor biopsies.
Time frame: Pre-treatment baseline, 1 week after Day 1
90Y-NM600 Tumor Microenvironment Immunologic Activation
Sorted CD45+ cells isolated from disaggregated tumor biopsies will be analyzed by scRNAseq
Time frame: Pre-treatment baseline, 1 week after Day 1
Count of Circulating Tumor Cells (CTCs)
CTCs captured by CapioCyte will be quantified, radioactivity directly measured, and mRNA extracted for PCR analysis of PD-L1, MHC-1, VCAM-1, and IFNβ expression.
Time frame: Pre-treatment baseline, 1 week after Day 1
Radioactivity of Circulating Tumor Cells (CTCs)
CTCs captured by CapioCyte will be quantified, radioactivity directly measured, and mRNA extracted for PCR analysis of PD-L1, MHC-1, VCAM-1, and IFNβ expression.
Time frame: Pre-treatment baseline, 1 week after Day 1
Expression of Circulating Tumor Cells (CTCs)
CTCs captured by CapioCyte will be quantified, radioactivity directly measured, and mRNA extracted for PCR analysis of PD-L1, MHC-1, VCAM-1, and IFNβ expression.
Time frame: Pre-treatment baseline, 1 week after Day 1
Phenotype of CD8+ T cells
Peripheral blood mononuclear cells (PBMCs) will be sorted to isolate CD8+ T cells and these will be evaluated by IsoPlexis single cell proteomics assay and by deep sequencing of the T cell receptor.
Time frame: Pre-treatment, Every 4 weeks after Day 1
Mutation Burden of Circulating Tumor DNA
Measure changes in ctDNA fraction, tumor mutation burden, and the clonal evolution of tumors with treatment.
Time frame: Pre-treatment baseline, 1 week after Day 1
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.
Of 209 non-industry phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 22 months is below that.
Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison →